Want full text access to this journal?
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign UpJAMA Neurology
• journal#1
Fernando Pico, Bertrand Lapergue, Marc Ferrigno, Charlotte Rosso, Elena Meseguer, Marie-Laure Chadenat, Frederic Bourdain, Michael Obadia, Catherine Hirel, Duc Long Duong, Sandrine Deltour, Philippe Aegerter, Julien Labreuche, Amina Cattenoy, Didier Smadja, Hassan Hosseini, Benoit Guillon, Valérie Wolff, Yves Samson, Charlotte Cordonnier, Pierre Amarenco
Importance: Treatment with remote ischemic perconditioning has been reported to reduce brain infarction volume in animal models of stroke. Whether this neuroprotective effect was observed in patients with acute ischemic stroke remains unknown. Objective: To determine whether treatment with remote ischemic perconditioning administered to the leg of patients with acute ischemic stroke can reduce brain infarction volume growth. Design, Setting, and Participants: This proof-of-concept multicenter prospective randomized open-label with blinded end point clinical trial was performed from January 12, 2015, to May 2, 2018...
March 30, 2020: JAMA Neurology
#2
Kate Martin
No abstract text is available yet for this article.
March 30, 2020: JAMA Neurology
#3
Giulia Grande, Petter L S Ljungman, Kristina Eneroth, Tom Bellander, Debora Rizzuto
Importance: Emerging yet contrasting evidence associates air pollution with incident dementia, and the potential role of cardiovascular disease (CVD) in this association is unclear. Objective: To investigate the association between long-term exposure to air pollution and dementia and to assess the role of CVD in that association. Design, Setting, and Participants: Data for this cohort study were extracted from the ongoing Swedish National Study on Aging and Care in Kungsholmen (SNAC-K), a longitudinal population-based study with baseline assessments from March 21, 2001, through August 30, 2004...
March 30, 2020: JAMA Neurology
#4
Maya Vijayaraghavan
No abstract text is available yet for this article.
March 30, 2020: JAMA Neurology
#5
Merit Cudkowicz, Marianne K Chase, Christopher S Coffey, Dixie J Ecklund, Brenda J Thornell, Codrin Lungu, Katy Mahoney, Laurie Gutmann, Jeremy M Shefner, Kevin J Staley, Michael Bosch, Eric Foster, Jeffrey D Long, Emine O Bayman, James Torner, Jon Yankey, Richard Peters, Trevis Huff, Robin A Conwit, Shlomo Shinnar, Donna Patch, Basil T Darras, Audrey Ellis, Roger J Packer, Karen S Marder, Claudia A Chiriboga, Claire Henchcliffe, Joyce Ann Moran, Blagovest Nikolov, Stewart A Factor, Carole Seeley, Steven M Greenberg, Anthony A Amato, Sara DeGregorio, Tanya Simuni, Tina Ward, John T Kissel, Stephen J Kolb, Amy Bartlett, Joseph F Quinn, Kellie Keith, Steven R Levine, Nadege Gilles, Patricia K Coyle, Jessica Lamb, Gil I Wolfe, Annemarie Crumlish, Luis Mejico, Muhammad Maaz Iqbal, James D Bowen, Caryl Tongco, Louis B Nabors, Khurram Bashir, Melanie Benge, Craig M McDonald, Erik K Henricson, Björn Oskarsson, Bruce H Dobkin, Catherine Canamar, Tracy A Glauser, Daniel Woo, Angela Molloy, Peggy Clark, Timothy L Vollmer, Alexander J Stein, Richard J Barohn, Mazen M Dimachkie, Jean-Baptiste Le Pichon, Michael G Benatar, Julie Steele, Lawrence Wechsler, Paula R Clemens, Christine Amity, Robert G Holloway, Christine Annis, Mark P Goldberg, Mariam Andersen, Susan T Iannaccone, A Gordon Smith, J Robinson Singleton, Mariana Doudova, E Clarke Haley, Mark S Quigg, Stephanie Lowenhaupt, Beth A Malow, Karen Adkins, David B Clifford, Mengesha A Teshome, Noreen Connolly
Importance: One major advantage of developing large, federally funded networks for clinical research in neurology is the ability to have a trial-ready network that can efficiently conduct scientifically rigorous projects to improve the health of people with neurologic disorders. Observations: National Institute of Neurological Disorders and Stroke Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) was established in 2011 and renewed in 2018 with the goal of being an efficient network to test between 5 and 7 promising new agents in phase II clinical trials...
March 23, 2020: JAMA Neurology
#6
Blair R Leavitt, Holly B Kordasiewicz, Scott A Schobel
Huntington disease (HD) is caused by a cytosine-adenine-guanine trinucleotide repeat expansion in the huntingtin gene, HTT, that results in expression of variant (mutant) huntingtin protein (HTT). Therapeutic strategies that reduce HTT levels are currently being pursued to slow or stop disease progression in people with HD. These approaches are supported by robust preclinical data indicating that reducing variant huntingtin protein is associated with decreased HD pathology. However, the risk-benefit profile of reducing either variant HTT or both variant and wild-type HTT is currently an open question that is being addressed in ongoing clinical trials...
March 23, 2020: JAMA Neurology
#7
Claire André, Stéphane Rehel, Elizabeth Kuhn, Brigitte Landeau, Inès Moulinet, Edelweiss Touron, Valentin Ourry, Gwendoline Le Du, Florence Mézenge, Clémence Tomadesso, Robin de Flores, Alexandre Bejanin, Siya Sherif, Nicolas Delcroix, Alain Manrique, Ahmed Abbas, Natalie L Marchant, Antoine Lutz, Olga M Klimecki, Fabienne Collette, Eider M Arenaza-Urquijo, Géraldine Poisnel, Denis Vivien, Françoise Bertran, Vincent de la Sayette, Gaël Chételat, Géraldine Rauchs
Importance: Increasing evidence suggests that sleep-disordered breathing (SDB) increases the risk of developing Alzheimer clinical syndrome. However, the brain mechanisms underlying the link between SDB and Alzheimer disease are still unclear. Objective: To determine which brain changes are associated with the presence of SDB in older individuals who are cognitively unimpaired, including changes in amyloid deposition, gray matter volume, perfusion, and glucose metabolism...
March 23, 2020: JAMA Neurology
#8
S Andrew Josephson
No abstract text is available yet for this article.
March 23, 2020: JAMA Neurology
#9
Heather Finlay-Morreale
No abstract text is available yet for this article.
March 16, 2020: JAMA Neurology
#10
Andrew Peterson, Adrian M Owen, Jason Karlawish
No abstract text is available yet for this article.
March 16, 2020: JAMA Neurology
#11
Huan Song, Johanna Sieurin, Karin Wirdefeldt, Nancy L Pedersen, Catarina Almqvist, Henrik Larsson, Unnur A Valdimarsdóttir, Fang Fang
Importance: Posttraumatic stress disorder (PTSD) has been associated with increased risk for dementia. Less is known, however, about other stress-related disorders and their associations with neurodegenerative diseases. Objective: To examine the association between stress-related disorders and risk for neurodegenerative diseases. Design, Setting, and Participants: This population-matched and sibling cohort study was conducted in Sweden using data from nationwide health registers, including the Swedish National Patient Register...
March 9, 2020: JAMA Neurology
#12
Suradech Suthiphosuwan, Pascal Sati, Martina Absinta, Melanie Guenette, Daniel S Reich, Aditya Bharatha, Jiwon Oh
No abstract text is available yet for this article.
March 9, 2020: JAMA Neurology
#13
Ophir Keret, Tina D Hoang, Feng Xia, Howard J Rosen, Kristine Yaffe
Importance: The incidence of unprovoked seizures and epilepsy increases considerably in late life, with approximately one-third of seizures being of unknown etiology. While individuals with dementia have a high risk of developing unprovoked seizures, it is unknown whether older adults with late-onset unprovoked seizures of unknown etiology (LOSU) are at risk of developing dementia. Objective: To determine whether incident LOSU is associated with a higher risk of dementia among older US veterans...
March 9, 2020: JAMA Neurology
#14
Dingding Shen, Haiyan Zhou, Sheng Chen
No abstract text is available yet for this article.
March 9, 2020: JAMA Neurology
#15
Conrado J Estol
No abstract text is available yet for this article.
March 2, 2020: JAMA Neurology
#16
Adrian Budhram, Amy C Kunchok, Eoin P Flanagan
No abstract text is available yet for this article.
March 2, 2020: JAMA Neurology
#17
Ian Miller, Ingrid E Scheffer, Boudewijn Gunning, Rocio Sanchez-Carpintero, Antonio Gil-Nagel, M Scott Perry, Russell P Saneto, Daniel Checketts, Eduardo Dunayevich, Volker Knappertz
Importance: Clinical evidence supports effectiveness of cannabidiol for treatment-resistant seizures in Dravet syndrome, but this trial is the first to evaluate the 10-mg/kg/d dose. Objective: To evaluate the efficacy and safety of a pharmaceutical formulation of cannabidiol, 10 and 20 mg/kg/d, vs placebo for adjunctive treatment of convulsive seizures in patients with Dravet syndrome. Design, Setting, and Participants: This double-blind, placebo-controlled, randomized clinical trial (GWPCARE2) recruited patients from April 13, 2015, to November 10, 2017, with follow-up completed on April 9, 2018...
March 2, 2020: JAMA Neurology
#18
John Betjemann, J Claude Hemphill, Urmimala Sarkar
No abstract text is available yet for this article.
March 2, 2020: JAMA Neurology
#19
Stephen A Goutman, Eva L Feldman
No abstract text is available yet for this article.
March 2, 2020: JAMA Neurology
#20
Eric S Silberman
No abstract text is available yet for this article.
February 24, 2020: JAMA Neurology
Fetching more papers... 
